OPK-88004
Aliases: OPK88004
Last verified: 2026-09-23
The short version
A SARM with a unique profile: increases bone mass without enlarging the prostate — studied for osteoporosis and (paradoxically) BPH. Status: in clinical trials. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A SARM with a unique profile: increases bone mass without enlarging the prostate — studied for osteoporosis and (paradoxically) BPH.
Mechanism of action
Tissue-selective AR modulation; antiproliferative on prostate preclinically.
Dosing & routes
Official / clinical context
No approved official document exists for OPK-88004. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: 5–25 mg/day. No meaningful community experiences; trials show bone-density gains.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
No meaningful community experiences; trials show bone-density gains.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Phase II (OPKO Health): bone mineral density in men.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Mild GI upset, fatigue.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.